- 期刊
- OpenAccess
Current and Emerging Therapies in Peripheral T-cell Lymphoma: Focus on Pralatrexate
並列摘要
Peripheral T-cell lymphomas (PTCL) represent about 12%- 15% of non-Hodgkin lymphomas and are characterized for being a molecularly heterogenous group of diseases. The optimal treatment for PTCLs remains to be defined as they are usually refractory to existing therapies and carry a poor prognosis. Pralatrexate (PDX), a rationally designed antifolate drug, was granted FDA approval as a single agent for the treatment of relapsed/refractory PTCL in 2009. Because of its favorable toxicity profile and activity, Pralatrexate has become a major compound for patients with refractory PTCL.
延伸閱讀
- Tang, T., Tay, K., Quek, R., Tao, M., Tan, S. Y., Tan, L., & Lim, S. T. (2010). Peripheral T-Cell Lymphoma: Review and Updates of Current Management Strategies. Advances in Hematology, 2010(), 202-209. https://doi.org/10.1155/2010/624040
- Rowan, A. G., & Bangham, C. R. M. (2012). Is There a Role for HTLV-1-Specific CTL in Adult T-Cell Leukemia/Lymphoma?. Leukemia Research and Treatment, 2012(), 100-106. https://doi.org/10.1155/2012/391953
- Argyriou, P., Economopoulou, P., & Papageorgiou, S. (2012). The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas. Advances in Hematology, 2012(), 236-248. https://doi.org/10.1155/2012/435342
- 張景明、吳仁光（2016）。T-cell Lymphomas Overview and Recent Advances。內科學誌，27(3)，139-148。https://doi.org/10.6314/JIMT.2016.27(3).04
- Prodduturi, P., & Bierman, P. J. (2012). Current and Emerging Pharmacotherapies for Primary CNS Lymphoma. Clinical Medicine Insights: Oncology, (), 219-231. https://doi.org/10.4137/CMO.S7752